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Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S38Conclusions: Second UCBT resulted in acceptable survival
particularly in the recent years when used as a rescue for
failed initial UCBT. Use of a CBU allows quick second trans-
plants and thus decreases the overall duration of cytopenias.
Second UCBT should be offered as a viable option for children
with a failed ﬁrst UCBT.17
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Objective:We studied the outcome of heavily pre transfused
aplastic anemia patients receiving peripheral blood stem cell
transplant (PBSCT) from matched sibling donor.
Material: 72 consecutive blood/marrow stem cell trans-
plants in 69 aplastic anemia patients over a period of 10 years
in non HEPA ﬁltered single rooms were recorded. Fludar-
abine 30 mg/m
ˇ
2 D-10 to D-5, cyclophosphamide 60 mg/kg/
day D-6 to D-5 and antithymocyte globulin 30 mg/kg/day D-
4 to D-1 were used as conditioning regimen. Cyclosporine
and methotrexate were used for graft versus host disease
(GvHD) prophylaxis. ABO mismatched marrows underwent
RBC depletion. No attempt to reduce antibody titres was
done for ABO mismatched PBSCT.
Results: 63 patients underwent PBSCT; 2 underwent the
procedure twice, 1 of whom had relapsed as acute myeloid
leukemia. Of the 6 patients who received bone marrow stem
cells, 2 relapsed and 1 underwent a successful PBSCT from
the same donor. The median age of patients was 30 years
(range 4-40 years); median time to transplant was 13.5
months (range 1-65 months); median transfusions before
transplant were 22.5 (range 3-10). 28 (38.8%) patients had
pre-existing infections at time of transplant. 65 patients
received empirical antibiotics and 27 received empirical
antifungals for febrile neutropenia during transplant. Posi-
tive blood culture for bacteria was recorded in 10 patients
and a biopsy proven fungus (2 aspergillus, 2 mucor) in 4Figure 1a. Overall survival (OS) in months of 9 patients with SCA after Reduced Toxic
4-45 mo).patients; 5 other patients had possible fungal infection based
on radiological features.
All patients and donors were CMV IgG positive at base-
line. CMV reactivation was noted in 11 patients, 5 of whom
were on steroids for GVHD; 3 patients subsequently suffered
a graft failure.
55/72 (76%) patients are alive at median follow-up of 60
months ranging from 0-118 months. Acute GVHD was seen in
18/72 transplants (25%). 5 patients developed grade III-IV gut
acute GvHD; 4 died. Chronic GvHD was seen in 32% of cases
(20/62; 10 patients died before day 100). However these were
mostly associated with dry skin and changes in pigmentation
which generally subsided over time and well tolerated;1 pa-
tient had nephrotic syndrome at 3 years. Severe cGVHD as per
NIH criteria was seen in only 5 patients. 17 patients had ABO
major mismatch of which 5 patients developed PRCA. PRCA
was managed with steroids and erythropoietin; the longest
duration before recovery was 12 months. 17 patients died.
Cause of early death (<day 100) were: acute GVHD 4, intra-
cranial bleed 4, aspergillus 1, CMV 1, graft rejection 5 (more
than 1 possible cause in some). Cause of death > day 100:
chronic GVHD 1, graft rejection 2, tuberculosis 1.
Conclusions: PBSCT is safe in aplastic anemia patients whose
transplant has been delayed and thereby heavily pre-
transfused. The outcome and survival appear comparable to
those achieved with historical bone marrow transplant data
without apparent increase in morbidity on account of
chronic GvHD.18
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Figure 1b. VOC-free and transfusion-free survival(TFS) (in months) of 9 patients with SCA after reduced toxicity conditioning (RTC)with ATG-BU-Flu and allo-sibling
HSCT (median 22 mo; range4-45mo).
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AIM OF THE STUDY: to assess safety and efﬁcacy of pre-con-
ditioning use of prednisone and Hydroxyurea and Fludarabine,
iv-Busulfan and low dose ATG in young adults with SCA.Figure 2a. Cumulative incidence of aGVHD after reduced toxicity conditioning with ATPatients and Methods: Nine consecutive SCA patients,
median age 18 y (14-30y) transplanted between 23/1/11
and 1/7/14 from identical siblings (7 BM, 1 PB and
1 BM+PB), median CD34+ cell dose 5.8 x10_6/kg (2.7-
8.2).Indications of HSCT were recurrent severe VOC (n:9;
100%), Acute chest syndrome (n: 3; 33% ), stroke (2; 22% ),
AVN (n; 2; 22%. HLA-matching was 10/10 in all pairs 100%);
3 donors (33%) had sickle cell trait. One patient (11.1)
rejected a previous allosib-HSCT after Campath-based NMA
conditioning.
Preconditioning Phase: a) Cytoreduction with hydroxy-
urea plus prednisone 0.5mg/kg every other day for>3weeks.
CONDITIONING: FLU: 40mg/m2/d (d-9 to d-6), iv
Busulfan: 0.8mg/kg q6h x14 doses (d-7 to d-4) (total 11.2mg/
kg) and ATG(Thymoglobulin; Genzyme): 1.5mg/kg/d (d-4 to
d-2) (total 4.5mg/kg); 2 patients received 5.5 mg/kg.
GVHD PROPHYLAXIS: Cyclosporine (CSA) (d-1 to d+9
months) and Methotrexate (15mg/m2 d+1, 10mg/m2 d+3
and d+6). Supportive care was as per institutional protocol.G-BU-FLU and allogeneic sibling HSCTfor patients with sickle cell disease (n:9).
Figure 2b. Cumulative incidence of c-GVHD after reduced toxicity conditioning with ATG-BU-FLU and allogeneic sibling HSCT for patients with sickle cell disease (n:8).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S40Results: Median F/U was 22 mo (3.5-45 mo). All patients
tolerated prednisone-hydroxyurea; only one episode of short
(3days) neurtopenic fever occured before protocol evolution;
no case of VOC or ACS or stroke or worsening of AVN (cu-
mulative 109 weeks-patients).
Therewasno (0%) transplant relatedmortality (TRM)andall
are alive (OS 100%) and free of VOC and transfusion (TFS 100%).
Engraftment: ANC recovery occurred in all (100%) at amedian
of 19 days (range 0-26 d), Platelet recovery to 20,000/ul in 100%
at amedianof 16d (10-36) and to 50,000 in 100%at amedianof
16d (11-50 d); 8 patients (89%) reached 50,000 in 21d. Hb
electrophoresis changed to donor type. Chimerism: All patient
(100%) had full (100%) myeloid chimerism. Lymphoid chi-
merism was high (>50% donor) in 6 (67%), intermediate in 1
(11%) and ﬂuctuated between 15-31% in 2 (22%).
GVHD: One (11.1%) patient developed grade II a-GVHD,
responded to steroids and only one (12.5%) of the 8 evaluable
patients developed cGVHD that responded to steroids. Peri-
transplant morbidities: Mucositis occurred in 4 (44%; grade
I in 22%, grade II in 11% and Grade III in 11%); one (11%) pa-
tient bled due to gastritis, delayed serum sickness in 1 (11%).
4 (44%) had culture-neg neutropenic fever without sepsis
and 1 (11.1%) developed line related infection. No reported
invasive fungal disease or hemorrhagic cystitis.
Conclusions: Conditioning for allo-sib-HSCT for adults with
SCA could safely and effectively be divided into: 1) Pre-
conditioning phase with steroids and Hydroxyurea to help
reduce the chronic inﬂammatory status and 2)Reduced
Toxicity Conditioning with ATG-Bu-FLU which allowed
engraftment of all patients with no peri-transplant mortality
and low rate of acute and chronic GVHD.
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The Effect of Race, Socioeconomic Status, and Collection
Center Size on Bone Marrow (BM) and Peripheral Blood
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Multivariate analysis of BM donors for grade 2-4 pain by race/sex: Odds Ratio (p-v
(overall p-value) Hispanic Asian/ Paciﬁc Islander
Male (<0.01) 0.75 (0.21) 0.61 (0.10)
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Previous studies have identiﬁed risks of collection-related
pain and symptoms associated with sex, BMI, and age in
unrelated donors undergoing collection at NMDP centers.
We hypothesized that other important factors (race, socio-
economic status [SES], and collection center experience as
reﬂected by numbers of procedures performed) might affect
rates of pain/symptoms in donors. We assessed outcomes by
5 race categories (see Table 1), 4 SES levels, and collection
center volume. The study cohort included 2726 BM and 6768
PBSC donors collected between 2004 and 2009. Skeletal pain
and 10 symptoms were measured and scaled 1-4 as pub-
lished previously (Pulsipher, Blood 2013 121:197). Pain/
symptoms are reported as peak levels over mobilization and
collection (PBSC) or within 2 days of collection (BM) and at 1
week after collection. Generalized linear mixed models were
used to ﬁt logistic regression models with random effects by
center; the 3 main effects of race, SES, and center volume
were forced into themodel, while other donor characteristics
were added in a stepwise manner.
For PBSC donors, race was not associated with differences in
pain/symptoms during collection or 1-week post donation.
PBSC donors in higher SES levels reported higher peakalue).
Black White Other/ Unknown
1.91 (0.01) 1.0 0.63 (0.09)
0.57 (0.03) 1.0 1.29 (0.30)
